Phospholipid Research Center | Funded Projects
page-template-default,page,page-id-16569,page-child,parent-pageid-16563,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-15.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Funded Projects


Following projects have been supported by the Phospholipid Research Center:


  • Physico-chemical properties of mixed micelles and vesicles composed of phospholipids and surfactants (2007-2011). Prof. Dr. A. Blume, University of Halle-Wittenberg/Germany


  • Oral bioavailability screening of new drug compounds: comparison of the phospholipid vesicle based model with Caco-2 model (2007-2011). Prof. Dr. M. Brandl, University of Tromsø in cooperation with Prof. Dr. G. Fricker, University of Heidelberg/Germany


  • Phospholipid/Tetraether-lipid based liposomes for controlled drug delivery (2007-2011). Prof. Dr. G. Fricker, University of Heidelberg/Germany


  • Study of oral bioavailability of Mebudipine and Dibudipine upon administration in novel PhytoSolve formulation in rats (2010-2012). Dr. F. Keyhanfar, University of Teheran/Iran


  • Hydrogenated phospholipids as anti-metastatic agents (2008-2014). Prof. Dr. U. Massing, Clinic for Tumor Biology Freiburg/Germany


  • Phosphatidylcholines in anticancer drug delivery – mere innocent bystanders? (2008-2015) Dr. G. Puetz, University Hospital Freiburg/Germany


  • A lipid based drug delivery system for CNS applications (2010-2012). Dr. V. Reichel, University of Heidelberg/Germany


  • Using liposomes as carriers for plant derived polyphenolic antibacterial compounds (2010-2012). Dr. S. Ristori, University of Florence/Italy


  • The effect of foreign molecules on the physico-chemical properties of phospholipid bilayer membranes (liposomes). New applications of phospholipids for in-vitro toxicity studies of chemicals (2008-2011). Prof. Dr. F. Scholz, University of Greifswald/Germany


  • Caco-2 cell studies on lipid-mediated intestinal adsorption of active substances (2008-2011). Prof. Dr. R. Schubert, University of Freiburg/Germany


  • Liposomal delivery of curcumin and Curcuma extract as the anti-inflammatory and anticancer agents intended for vaginal therapy (2009-2010). Prof. Dr. N. Skalko-Basnet, University of Tromsø/Norway


  • Investigation of the retention of lipophilic drug compounds within liposomal drug carriers (2009-2016). Dr. S. Hupfeld, Oslo University College/Norway, Prof. Dr. M. Brandl, University of Southern Denmark/Odense/Denmark


  • Investigation of cochleate formulation and cochleate-cell membrane interactions (2011-2015). Prof. Dr. A. Fahr, University Jena/Germany


  • Phospholipid complexation as toolbox for improving anti-inflammatory treatment (2013-2014). Dr. M. Tawab, Zentrallaboratorium Deutscher Apotheker GmbH/Eschborn/Germany


  • Mechanistic action and adverse event of therapy with delayed release – Phosphatidylcholine in a genetic mouse model of ulcerative colitis (2012-2015). Prof. Dr. W. Stremmel, University Clinic Heidelberg/Germany


  • Phospholipid/Tetraetherlipid based liposomes for oral administration of Hepatitis B Virus-derived lipopeptides for hepatocyte-specific drug delivery (2012-2014). Prof. Dr. G. Fricker, Prof. Dr. W. Mier, Prof. Dr. S. Urban, University Heidelberg/Germany


  • Distribution of phospholipid based drug carriers into organs and tumors – monitoring by mass spectrometry imaging (2012-2014). Prof. Dr. C. Hopf, University Mannheim/Germany


  • Studies on monoacyl lecithin complexes with poorly soluble drugs – which compounds benefit particular from a dissolution enhancement regarding improved oral bioavailability? (2013-2016) Prof. Dr. M. Kuentz, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz/Switzerland


  • Phospholipid-based solid dispersions for enhanced oral absorption of poorly soluble drugs (2013-2017). Prof. Dr. A. Bauer-Brandl, University of Southern Denmark/Odense/Denmark


  • Interactions of the tumour-targeting vector peptide pHLIP with phospholipids (2012-2017). Prof. Dr. S. Keller, University Kaiserslautern/Germany


  • Inhibitory effect of phospholipids on the efflux transporter P-glycoprotein (Since 2013). Prof. Dr. R. Schubert, University Freiburg/Germany


  • Impact of phospholipid oxidation on biophysical properties of membranes (2012-2015). Prof. Dr. M. Tanaka, University Heidelberg/Germany


  • Oral anticancer-indirubins: Solubility enhancement, permeability and bioavailability assessment of SMEDDS formulations (2012-2017). Dr. A. Mahringer, University Heidelberg/Germany


  • The investigation of the interaction of liposomal formulations containing poorly water soluble drugs with human plasma (2013-2016). Prof. Dr. A. Fahr, University Jena/Germany


  • Elucidating the use of lyso-phospholipids in oral self-nanoemulsifying drug delivery systems (2013-2017). Prof. Dr. A. Müllertz, Copenhagen/Denmark


  • In vivo detoxification of alcohol using phospholipids supported bioreactors (2013-2017). Prof. Dr. J.-Ch. Leroux, ETH Zurich/Switzerland


  • Interaction of phospholipids with the skin in human subjects (2014-2016). Dr. M. Lane, University London/United Kingdom


  • Assessment and better prediction of acute hypersensitivity and complement involvement upon administering liposomal drug products to human subjects (2014-2019). Dr. J. Metselaar, University Twente/The Netherlands/Prof. Dr. J. Szebeni, Semmelweis University/Budapest/Hungary


  • Design of well-defined liposomes to target tumor-associated M2 macrophages (2015-2018). Dr. J. Prakash, University Twente/Utrecht/The Netherlands


  • Improving treatment of pediatric sarcomas through targeted liposomal drug delivery (2015-2017). Dr. M. Bernasconi, University Children’s Hospital Zurich/Switzerland


  • Development of NLCs and nanoemulsions with monoacyl-phospholipids and investigation of their skin penetration and influence on skin barrier structure in vitro and in vivo (2015-2018). Prof. Dr. C. Valenta, University Wien/Austria


  • Inhibition of Akt by polyunsaturated phosphatidylcholine – A novel approach for anti-cancer therapy (Since 2015). Dr. A Köberle, University Jena/Germany


  • Phospholipid microemulsions for the dermal application of proteins: Prediction of in-vivo skin tolerability with full-thickness human skin equivalent (2015-2016). PD Dr. R. Scherließ, University Kiel/Germany


  • Phospholipids as functional excipient in solid oral dosage forms (2015-2018). Prof. Dr.R.Bodmeier, FU Berlin/Germany


  • Physicochemical characterization of natural phospholipid excipients and development of colloidal carrier systems for active substances (micro-emulsions) on the basis of phospholipids for dermal application (Since 2015). Prof. Dr. R. Neubert, University Halle (Saale)/Germany and Prof. Dr. G. Brezesinski, Max-Planck-Institute for Colloid and Interface Research/Potsdam/Germany


  • Treatment and diagnosis of early gastric cancer with lipid based formulated Hypericin by applying photodynamic therapy (2015-2019).Dr. F. Helm, University Heidelberg/Germany


  • A phospholipid-functionalized calcium carbonate based drug delivery system to improve the bioavailability of poorly water-soluble drugs (Since 2016). Prof. Dr. J. Huwyler, University Basel/Switzerland


  • Phosphatidylserine enriched phospholipids as anti-inflammatory agents (Since 2015). Prof. Dr. K. Mäder, University Halle (Saale)/Germany


  • Phospholipid based liquid-fill formulations for hard capsules
    (Since 2015). 
    Prof. Dr. H. Bunjes, University Braunschweig/Germany


  • Establishing a more rational design of thermo-responsive liposomes (Since 2016). Prof. Dr. H. Heerklotz, University Freiburg/Germany


  • On-demand amplification of chemotherapy by ultra-fast drug release from plasmonic liposomes (2016-2018). Dr.  Xiuying Li. University of Dallas/USA


  • Development of a phospholipid-based depot technology for sustained drug release (Since 2016). Prof. Dr. P. Luciani, University Jena/Germany


  • Evaluation of cochleates as parenteral depot formulations
    (Since 2017).
     Prof. Dr. J. Kuntsche. University of Southern Denmark/Odense/Denmark


  • Liposomal oral drug delivery: The use of bipolar amphiphiles to stabilize liposomes (Since 2017). Dr. S. Drescher, University Halle/Germany.


  • Investigation of liposomal transdermal drug delivery by Raman microscopic imaging in combination with stable isotopic labelling as a new non-invasive modality to study drug penetration (Since 2016). Dr. Ch. Matthaeus, University Jena/Germany


  • Theranostic phospholipid-coated ultrasound contrast agents: response on demand (Since 2017). Dr. K. Kooiman,Erasmus University Medical Center Rotterdam/The Netherlands


  • Production of liposomes by centrifugation of water in oil emulsions (Since 2016). Prof. Dr. H. Nirschl, Karlsruhe Institute for Technology (KIT)/Germany


  • Synergy-based delivery system for combating sexually-transmitted bacterial infections: liposomal azithromycin-in-chitosan hydrogel (2017-2018). Prof. Dr. Z. Vanić, University Zagreb/Croatia


  • Antitubercular drug-loaded multi-liposomes vectors (Since 2017). Prof. F. Bordi, University Rome/Italy


  • Lipid nanovectors to use non-coding RNA oligonucleotides in glioblastoma in combination with standard therapy (Since 2017). Prof. Dr. G. de Rosa, University Frederico II Naples/Italy


  • Targeted liposomal antioxidant and anti-inflammatory therapy for liver ischemic reperfusion injury (Since 2017). Dr. L. Corvo, University Lisbon/Portugal


  • Phospholipids as metastases-targeting molecules using barcoding as a new research tool in liposome discovery (Since 2018). Prof. Dr. A. Schroeder. Israel Institute of Technology/Israel.


  • Research on the loading of exosomes (Since 2018). Prof. Dr. J.-C. Leroux. ETH Zurich/Switzerland.


  • Development and analysis of different phospholipid formulations for dermal application and their effect on human dermal cell viability (Since 2018). Prof. Dr. C. Valenta. University of Vienna/Austria.


  • Theoretical model to describe formation and stability of liposome-drug complexes (Since 2018). Prof. S. May. North Dakota State University/USA.


  • Bottom-up designed synthetic bacteria – a tool to develop new antibiotic strategies (Since 2018). Prof. Dr. T. Gutsmann. Forschungszentrum Borstel/Germany.


  • Liposome – Extracellular Vesicle Hybrids for Therapeutic RNA Delivery (Since 2018). Prof. R. M. Schiffelers. University Medical Center Utrecht/The Netherlands.


  • Development of phospholipid-based antimalarial tablets of azadirachta indica leaf extract and artemether/lumefantrine for oral delivery
    (Since 2018).
    Prof. A. A. Attama, University of Nigeria/Africa